Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type 1 selected

Type

Guidance programme

Showing 126 to 150 of 1904

TitleReference numberPublishedLast updated
Devices for remote monitoring of Parkinson's diseaseDG51
COVID-19 rapid guideline: managing the long-term effects of COVID-19NG188
Pharyngeal electrical stimulation for neurogenic dysphagiaIPG781
Temperature control to improve neurological outcomes after cardiac arrestIPG782
Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancerTA946
Early and locally advanced breast cancer: diagnosis and managementNG101
Durvalumab with gemcitabine and cisplatin for treating unresectable or advanced biliary tract cancerTA944
Sebelipase alfa for treating Wolman diseaseHST30
Intravascular lithotripsy for calcified arteries in peripheral arterial diseaseIPG780
Bipolar disorder: assessment and managementCG185
Targeted-release budesonide for treating primary IgA nephropathyTA937
Ravulizumab for treating generalised myasthenia gravis (terminated appraisal)TA940
Ravulizumab for treating AQP4 antibody-positive neuromyelitis optica spectrum disorder (terminated appraisal)TA941
Empagliflozin for treating chronic kidney diseaseTA942
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetesTA943
Risdiplam for treating spinal muscular atrophyTA755
Digitally enabled therapies for adults with anxiety disorders: early value assessmentHTE9
Middle meningeal artery embolisation for chronic subdural haematomasIPG779
Cardiovascular disease: risk assessment and reduction, including lipid modificationNG238
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Velmanase alfa for treating alpha-mannosidosisHST29
Dupilumab for treating eosinophilic oesophagitis in people 12 years and over (terminated appraisal)TA938
Acne vulgaris: managementNG198
Secukinumab for treating moderate to severe hidradenitis suppurativaTA935
Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma after 3 or more treatments (terminated appraisal)TA936

Results per page

  1. 10
  2. 25
  3. 50
  4. All